The Soliris® Education Center for HCPs

Providing valuable insights about Soliris

View an interactive, educational presentation about the benefits of treating your PNH patients with Soliris, or choose from a variety of different publications, brochures, or tools.

Receive a complimentary* Bronze PhRMA Card (a $25 value) when you learn more about Soliris

View an interactive, educational presentation, designed to highlight the benefits of PNH treatment and management with Soliris. Once you have completed the presentation you’ll receive a complimentary* Bronze PhRMA Card (a $25 value).

Click here to begin

Brochures and Tools

Focused on a range of topics, these brochures can provide you with a better understanding of PNH and Soliris. There are also tools designed to supplement your practice.

Click here to see a list of downloadable PDFs. You can also log in or register to order a hard copy today.

Publications

Published in the top journals for hematologists and oncologists, these papers can provide you with critical information about PNH and how Soliris has benefited patients in numerous clinical trials.

Click here to order your copies.





IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

Soliris increases the risk of meningococcal infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early

  • Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use
  • Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary

The effect of withdrawal of anticoagulant therapy during Soliris treatment has not been established. Therefore, treatment with Soliris should not alter anticoagulant management.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, and fatigue.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.


*For US physicians only. Allowed in all states except DC, MA, ME, MN, and VT.